¼¼°èÀÇ ±Û·çÄÚ»ç¹Î ½ÃÀå
Glucosamine
»óǰÄÚµå : 1513927
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 167 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

±Û·çÄÚ»ç¹Î ¼¼°è ½ÃÀåÀº 2030³â±îÁö 17¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 11¾ï ´Þ·¯·Î ÃßÁ¤µÈ ±Û·çÄÚ»ç¹Î ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 17¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 6.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿µ¾ç º¸ÃæÁ¦ ¾ÖÇø®ÄÉÀ̼ÇÀº CAGR 7.2%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 12¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÄÀ½·á ÀÀ¿ë ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 2¾ï 8,770¸¸ ´Þ·¯, Áß±¹Àº CAGR 10.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±Û·çÄÚ»ç¹Î ½ÃÀåÀº 2023³â 2¾ï 8,770¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2023-2030³â°£ CAGR 10.4%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 4¾ï 2,740¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.7%¿Í 5.4%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ±Û·çÄÚ»ç¹Î ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±Û·çÄÚ»ç¹ÎÀº ÀÎü¿¡ ÀÚ¿¬ÀûÀ¸·Î Á¸ÀçÇÏ´Â È­ÇÕ¹°·Î, °üÀý ³» ¿¬°ñÀÇ ¹ß´Þ°ú À¯Áö¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. È­ÇÐÀûÀ¸·Î´Â ¾Æ¹Ì³ë´çÀ¸·Î ºÐ·ùµÇ¾î ü³»ÀÇ ´Ù¾çÇÑ ±â´É ºÐÀÚÀÇ Çü¼º, ƯÈ÷ °üÀýÀÇ Äí¼ÇÀÌ µÇ´Â À¯¿¬ÇÑ Á¶Á÷ÀÎ ¿¬°ñÀÇ À¯Áö¿¡ ÇʼöÀûÀÔ´Ï´Ù. ±Û·çÄÚ»ç¹ÎÀº ÀÚ¿¬°è¿¡¼­ »ý¼ºµÇÁö¸¸, ÁÖ·Î Á¶°³, µ¿¹°ÀÇ »À, ±Õ·ù¿¡¼­ ¾òÀº ¿µ¾ç º¸Á¶ ½ÄǰÀ¸·Îµµ ³Î¸® ¼·ÃëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¸ÃæÁ¦´Â °üÀýÀÇ °Ç°­À» ÁõÁø½ÃŰ°í °ñ°üÀý¿°(OA)°ú °°Àº Áõ»óÀ» Ä¡·áÇÏ´Â È¿°ú¸¦ ±â´ëÇÒ ¼öÀÖ´Â °ÍÀ¸·Î ÆÇ¸ÅµË´Ï´Ù. ±Û·çÄÚ»ç¹Î º¸ÃæÁ¦´Â °üÀý ¿¬°ñ°ú Ȱ¾× °Ç°­À» Áö¿øÇÏ°í ¸¶ÂûÀ» ÃÖ¼ÒÈ­ÇÏ°í °üÀýÀÇ ¿òÁ÷ÀÓÀ» ºÎµå·´°ÔÇÏ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù. ¼³¹® Á¶»ç´Â ƯÈ÷ ¿îµ¿ ¼±¼ö¿Í ½ÅüÀû ºÎÇϰ¡ ³ôÀº »ç¶÷ÀÌ ¿¬°ñ ÆÄ±«¸¦ ¿¹¹æÇÒ °¡´É¼ºÀ» ½Ã»çÇÏÁö¸¸, OA Ä¡·á¿¡¼­ ±Û·çÄÚ»ç¹ÎÀÇ Àü¹ÝÀûÀÎ È¿´ÉÀº ¾ÆÁ÷ °á·ÐÀÌ ³ª¿ÀÁö ¾Ê¾Ò½À´Ï´Ù.

±Û·çÄÚ»ç¹ÎÀº °üÀý °Ç°­¿¡ µµ¿òÀÌ µÉ»Ó¸¸ ¾Æ´Ï¶ó Ç× ¿°Áõ È¿°úµµ ÀÖ½À´Ï´Ù. ±Û·çÄÚ»ç¹Î º¸ÃæÁ¦°¡ ¿°Áõ ¸¶Ä¿ÀÎ C-¹ÝÀÀ¼º ´Ü¹éÁú(CRP)ÀÇ ¼öÁØÀ» °¨¼Ò½ÃŰ´Â °ÍÀÌ ¿¬±¸¿¡ Á¦½ÃµÇ¾î ÀÖÀ¸¸ç, ¿°Áõ »óÅÂÀÇ °ü¸®¿¡ µµ¿òÀÌ µÉ °¡´É¼ºÀÌ Á¦½ÃµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Á¶»ç °á°ú¿¡µµ ºÒ±¸Çϰí, ±Û·çÄÚ»ç¹ÎÀÌ Ç׿°Áõ ÀÛ¿ëÀ» ¹ßÈÖÇÏ´Â Á¤È®ÇÑ ¸ÞÄ¿´ÏÁòÀº ¿ÏÀüÈ÷ ¹àÇôÁöÁö ¾Ê¾Ò½À´Ï´Ù. ±Û·çÄÚ»ç¹ÎÀº ±Û·çÄÚ»ç¹Î Ȳ»ê¿°, ±Û·çÄÚ»ç¹Î ¿°»ê¿°, N-¾Æ¼¼Æ¿±Û·çÄÚ»ç¹Î µî ´Ù¾çÇÑ ÇüÅ·ΠÆÇ¸ÅµÇ°í ÀÖÁö¸¸, Ç׿°Áõ ÀÛ¿ë¿¡ Å« Â÷ÀÌ´Â ¾ø½À´Ï´Ù. ÀϹÝÀûÀÎ ¼·Ãë·®Àº ÇÏ·ç 1500-3000mg·Î ÇÑ ¹ø¿¡ ¼·ÃëÇϰųª ºÐÇÒÇÏ¿© ¼·ÃëÇØµµ µË´Ï´Ù. ´ëºÎºÐÀÇ ÀÓ»ó ¿¬±¸´Â ±Û·çÄÚ»ç¹Î Ȳ»ê¿°¿¡ ÃÊÁ¡À» ¸ÂÃß°í Á¾Á¾ Äܵå·ÎÀÌÆ¾ Ȳ»ê¿°°ú ÇÔ²² »ç¿ëÇÏ¿© °ñ°üÀý¿°ÀÇ Áõ»ó¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÕ´Ï´Ù.

±Û·çÄÚ»ç¹Î ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. º¸ÃæÁ¦ Á¦Á¶¿¡ À־ÀÇ ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ º¸´Ù °íǰÁúÀ̰í È¿°úÀûÀÎ ±Û·çÄÚ»ç¹Î Á¦Ç°ÀÇ »ý»êÀÌ °¡´ÉÇÏ°Ô µÇ¾ú½À´Ï´Ù. µô¸®¹ö¸® ½Ã½ºÅÛÀÇ Çõ½ÅÀº ±Û·çÄÚ»ç¹ÎÀÇ »ýüÀÌ¿ë·ü°ú Èí¼ö¼ºÀ» Çâ»ó½ÃÄÑ º¸´Ù Æø³ÐÀº ¼ÒºñÀÚÃþ¿¡ ¾îÇÊÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±Û·çÄÚ»ç¹Î°ú °°Àº º¸ÃæÁ¦¸¦ ÅëÇØ ´õ ¸¹Àº ¼ÒºñÀÚ°¡ Àû±ØÀûÀ¸·Î °Ç°­À» À¯ÁöÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼°èÀÇ ³ëÈ­·Î ÀÎÇØ °üÀýÀÇ °Ç°­°ú °¡µ¿¼ºÀ» Áö¿øÇÏ´Â º¸ÃæÁ¦ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¶ÄÉÆÃ ³ë·ÂÀ¸·Î ´ë»óÃþÀº ³ëÀλӸ¸ ¾Æ´Ï¶ó ¿îµ¿¼±¼ö¿Í ½ÅüȰµ¿ÀûÀÎ »ç¶÷µé µî ÀþÀºÃþ¿¡µµ ÆÛÁö°í ÀÖ½À´Ï´Ù. ±Û·çÄÚ»ç¹ÎÀÇ È¿´É¿¡ ´ëÇÑ ¼ÒºñÀÚ ±³À° Áõ°¡¿Í ÀÌ·¯ÇÑ º¸ÃæÁ¦¸¦ »ó¾÷ÀûÀ¸·Î ½±°Ô ¾òÀ» ¼ö ÀÖµµ·ÏÇÏ´Â ±ÔÁ¦ ȯ°æÀÇ Á¤ºñ°¡ ±× ä¿ëÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ±Û·çÄÚ»ç¹Î º¸ÃæÁ¦´Â ºñ±³Àû Àû´çÇÑ °¡°ÝÀ¸·Î ³Î¸® ÀÌ¿ë °¡´ÉÇϱ⠶§¹®¿¡ °æÁ¦ÀûÀ¸·Î »ç¿ëÇϱ⠽±°í °üÀý °Ç°­ Áö¿øÀ» ¿ä±¸ÇÏ´Â »ç¶÷µé¿¡°Ô ¸Å·ÂÀûÀÎ ¼±ÅÃÀ̵Ǿú½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº Á¾ÇÕÀûÀ¸·Î ±Û·çÄÚ»ç¹Î º¸ÃæÁ¦ÀÇ ¼ºÀå°ú º¸±ÞÀ» ÃËÁøÇϰí, ±â¼úÀÇ Áøº¸, ¼ÒºñÀÚ ÇൿÀÇ º¯È­, ÁøÈ­ÇÏ´Â ½ÃÀå ¿ªÇÐÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 11°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Glucosamine Market to Reach US$1.7 Billion by 2030

The global market for Glucosamine estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Nutritional Supplements Application, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Food & Beverages Application segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$287.7 Million While China is Forecast to Grow at 10.4% CAGR

The Glucosamine market in the U.S. is estimated at US$287.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$427.4 Million by the year 2030 trailing a CAGR of 10.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Glucosamine Market - Key Trends and Drivers Summarized

Glucosamine, a naturally occurring compound in the human body, plays a crucial role in developing and maintaining cartilage within joints. It is classified chemically as an amino sugar and is essential for the formation of various functional molecules in the body, particularly in the maintenance of cartilage, the flexible tissue that cushions joints. Although glucosamine is produced naturally, it is also widely consumed as a dietary supplement, primarily derived from shellfish shells, animal bones, or fungi. These supplements are marketed for their potential benefits in enhancing joint health and treating conditions like osteoarthritis (OA). Glucosamine supplements aim to support the health of articular cartilage and synovial fluid, minimizing friction and facilitating smooth joint movement. Research suggests that these supplements might prevent cartilage breakdown, particularly in athletes and individuals with high physical demands, although the overall efficacy of glucosamine in treating OA remains inconclusive.

Beyond its role in joint health, glucosamine is noted for its anti-inflammatory properties. Studies have indicated that glucosamine supplements can reduce levels of C-reactive protein (CRP), a marker of inflammation, suggesting potential benefits for managing inflammatory conditions. Despite these findings, the exact mechanisms through which glucosamine exerts its anti-inflammatory effects are not fully understood, and ongoing research continues to explore its impact on inflammation-related ailments. Glucosamine is available in various forms, including glucosamine sulfate, glucosamine hydrochloride, and N-acetyl glucosamine, with no significant differences in their anti-inflammatory properties. Typical dosages range from 1500 to 3000 mg per day, which can be taken all at once or in divided doses. Most clinical studies have focused on glucosamine sulfate, often in combination with chondroitin sulfate, to assess its impact on osteoarthritis symptoms.

The growth of the glucosamine market is driven by several key factors. Technological advancements in supplement manufacturing have enabled the production of higher quality and more effective glucosamine products. Innovations in delivery systems have improved the bioavailability and absorption of glucosamine, making it more appealing to a broader consumer base. There is a growing trend towards self-care and preventative health measures, with more consumers proactively maintaining health and wellness through supplements like glucosamine. Additionally, the aging global population is increasing the demand for supplements that support joint health and mobility. Marketing efforts have expanded the target demographics to include not only the elderly but also younger individuals, such as athletes and physically active people. Increased consumer education about the benefits of glucosamine, along with a favorable regulatory environment that makes these supplements easily accessible over the counter, further supports its adoption. Finally, the economic accessibility of glucosamine supplements, being relatively affordable and widely available, makes them an attractive option for those seeking joint health support. These factors collectively drive the growth and widespread adoption of glucosamine supplements, reflecting advancements in technology, changing consumer behaviors, and evolving market dynamics.

Select Competitors (Total 11 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â